Phase II clinical study of CAR-T-19 (anti-CD19 single chain antibody chimeric antigen receptor T cell) injection in the treatment of CD19 positive recurrent/refractory B-cell acute lymphoblastic leukemia under 25 years old (inclusive)
Chinese Academy of Medical Sciences Hematology Hospital
Beijing Boren Hospital
Beijing Children's Hospital Affiliated to Capital Medical University
Peking University People's Hospital
Capital Institute of Pediatrics Affiliated Children's Hospital
Henan Cancer Hospital
Shandong University Qilu Hospital
Anhui Children's Hospital
The First Affiliated Hospital of Zhengzhou University
Shanxi Cancer Hospital
Xuzhou Medical University Affiliated Hospital
Children's Hospital Affiliated to Zhejiang University School of Medicine
The First Affiliated Hospital of Nanchang University
Xiangya Second Hospital of Central South University
West China Second Hospital of Sichuan University
Harbin Institute of Hematology
Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital
If you meet the following conditions:
Understand and voluntarily sign the informed consent form;
Age 25 years old or younger, gender not limited during screening;
The bone marrow examination confirmed the diagnosis of acute B-cell leukemia and met one of the following two conditions:
1. Recurrent B-ALL:
(Recurrence within 12 months after first remission; Late recurrence (≥ 12 months) after first remission) Recurrence or no remission after first-line/multi line salvage chemotherapy; Having experienced 2 or more bone marrow relapses; Recurrence after autologous or allogeneic hematopoietic stem cell transplantation);
2. Refractory B-ALL:
(For those who have not achieved complete remission after two courses of standardized induction chemotherapy at the initial diagnosis); During the screening period, CD19 expression was measured in bone marrow (BM) or peripheral blood (PB) tumor cells;
Expected survival period is at least 12 weeks;
Having sufficient venous access (for single collection) and no other contraindications for blood cell isolation;
So you may meet the inclusion criteria for this study.